Table 4 Summary of meta-analysis results in the achievement of the virological outcome by Pegylated interferon α-2a and α-2b plus ribavirin in patients with genotype 1 chronic hepatitis C

4 [17–19, 22]

1,374/1,355

186(13.5)/174(12.8)

1.05

0.87–1.27

0.62

3.8;0.28;21.1

5[17–19, 21, 22]

1,395/1,371

649(46.5)/572(38.4)

1.12

1.03–1.22

0.011

7.58;0.14;42.8

5[16, 18, 19, 21, 22]

1,243/1,217

782(62.9)/627(51.5)

1.22

1.14–1.31

<0.0001

7.6;0.11;47.3

5^*[16, 18, 19, 21, 22]

921/879

544(59)/403(45.8)

1.29

1.18–1.41

<0.0001

8.37;0.08;52.1

6[16, 18–22]

1,336/1,310

574(43)/521(39.8)

1.08

0.99–1.18

0.098

9.97;0.08;49.8

6^**[16, 18–22]

1,058/732

473(44.7)/306(41.8)

1.08

0.97–1.20

0.19

10.9;0.053;54.2

6^*[16, 18–22]

1,014/972

406(40)/346(35.5)

1.13

1.01–1.26

0.04

8.59;0.13;41.8